MHRA fees

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated guidance regarding service fees for the period spanning 2025 to 2027. This document outlines revised costs associated with marketing authorizations, clinical trial applications, and manufacturing licenses within the United Kingdom. As this is a general regulatory fee update rather than an individual inspection report, there is no specific company name or set of inspection dates identified. Instead, the document establishes a broader regulatory framework for cost recovery under UK pharmaceutical legislation. The primary focus of the guidance is the implementation of phased fee increases across most service categories to ensure the agency remains adequately funded to protect public health. While no violations are cited, the document serves as a notification of the administrative requirements for maintaining compliance. Required actions for industry stakeholders include a thorough review of the updated schedules and the adjustment of internal budgets to align with the new rates. Stakeholders must ensure that all regulatory submissions and annual maintenance fees from 2025 onwards reflect these changes to avoid processing delays or administrative rejections. This proactive planning is essential for organizations operating within the UK healthcare sector to maintain seamless regulatory alignment.